PharmOptima LLC and Jeffrey L. Edelman, Ph.D. form Joint Research Alliance
PORTAGE, MICHIGAN, January 11, 2013; PharmOptima (Portage, Michigan) has recently signed an agreement with Jeffrey L. Edelman, Ph.D. of Ocular Research Solutions (Irvine, California) to set-up and validate a translational model of VEGF-induced vascular leakage. Dr. Edelman has 30 years of cumulative experience in ocular research and drug development and published on multiple ocular models including the VEGF vascular leak model which continues to be integral to the development of therapeutic treatments for retinal diseases including age-related macular degeneration (AMD). More than 9 million people in the United States suffer with some form of AMD, and in those people aged 65 and over wet AMD is the leading cause of blindness if not chronically treated over the lifetime of the patient. PharmOptima will use the VEGF-induced vascular leakage model as a tool in developing and refining AMD therapies in collaboration with researchers from across the globe.
Speaking for PharmOptima, Mr. A. Christian Schauer, CEO added, “Our alliance with Dr. Edelman brings a unique capability and specialty to our contract research business. Many of our clients are looking to us to provide professional solutions, and Dr. Edelman’s expertise and experience provides us with valuable insight and knowledge to meet those needs in ophthalmic research.”
PharmOptima, LLC (www.pharmoptima.com) is a contract research organization (CRO) advancing drug discovery by providing both in vitro and in vivo services. PharmOptima’s areas of in vitro expertise include biochemistry, protein cloning and expression, cell-based assays, immunosorbent assays (both traditional ELISA’s and electrochemiluminescent MSD formats) and biomarker research. In vivo research services include delivery, efficacy, tolerance, pharmacokinetics and ADME. In addition to being a premier provider of spinal muscular atrophy research, PharmOptima is also recognized as a leading CRO conducting ocular research.
Mr. A. Christian Schauer, CEO